SCARD Pool report for 01-01-2001 to 31-12-2001

Participants	Doctors	11	
	Patients	71	
Specimens	New lesions	131	79.88%
	Previously biopsied lesions	33	20.12%
	Total lesions	164	100.00%

Breakdown of new versus previously biopsied specimens



Percentage of new lesions tested which were malignant	70.54%
Percentage of Definitively excised lesions that were malignant	70.08%
Lesions tested to find one melanoma (NNT)	1.36
Percentage of lesions tested for NMSC which were NMSC	69.57%
Ratio of New BCCs : New Melanomas	4:1

Accuracy

Diagnostic sensitivity

Melanomas	72.73% of 11
All NMSC	81.25% of 80
BCCs	86.96% of 46
SCCs	50.00% of 34

Positive predictive value

Melanomas	80.00% of 10
All NMSC	84.42% of 77
BCCs	51.95% of 77
SCCs	68.00% of 25

Adequacy

Percentage of definitively managed malignant cases where surgical margins were adequate

BCC	80.00% of 20
IEC/Bowens disease	100.00% of 2
SCC	100.00% of 3
Keratoacanthoma	100.00% of 1
Melanoma - in situ	100.00% of 2
Melanoma - invasive	100.00% of 8
Melanoma - invasive > 1mm	0% of 0
Other malignant	0% of 0

© 2026 SCARD Systems Pty Ltd

Lesion Breakdown

Histological Diagnosis

BCC (unspecified type)	4	3.05%
BCC - Superficial	22	16.79%
BCC - Nodular/Solid	15	11.45%
BCC - Aggressive	5	3.82%
IEC/Bowens disease	25	19.08%
SCC	8	6.11%
Keratoacanthoma	1	0.76%
Pinkus Fibroepithelioma	0	0%
Merkel cell tumour	0	0%
Other malignant	0	0%
NMSC Metastasis	0	0%
Melanoma - in situ	3	2.29%
Melanoma - invasive	8	6.11%
Melanoma - invasive > 1mm	0	0%
Melanoma - metastasis	0	0%
MELTUMP	0	0%
Naevus - other	0	0%
Naevus - dysplastic/Clark	5	3.82%
Naevus - blue	0	0%
Naevus - Spitz/Reed	0	0%
Naevus - Compound	0	0%
Solar keratosis	27	20.61%
Solar lentigo	0	0%
Seborrhoeic keratosis	2	1.53%
Lentigo Simplex	0	0%
Lichenoid keratosis (LPLK)	0	0%
Dermatofibroma	2	1.53%
Sebaceous gland hyperplasia	1	0.76%
Benign cyst	0	0%
Other benign	1	0.76%
Histology Pending	0	0%



© 2026 SCARD Systems Pty Ltd

Procedures

Definitive Surgical Management used to exclude melanoma

Ellipse	6	85.71%
Flap	1	14.29%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	0	0%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	0	0%

Biopsy used to exclude melanoma

Punch - sample	2	25.00%
Shave - sample	0	0%
Incisional	0	0%
Punch - removal	0	0%
Shave - removal	0	0%
Excisional	6	75.00%
Curettage	0	0%
Other	0	0%

Breakdown of definitive management procedures for malignant conditions

Ellipse	29	32.22%
Flap	0	0%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Curettage & Cautery	46	51.11%
Liquid N2 freeze/thaw	0	0%
PDT	0	0%
Imiquimod	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	13	14.44%
Other	2	2.22%

Breakdown of definitive management procedures for benign conditions

Ellipse	6	13.95%
Flap	1	2.33%
Graft - SSG	0	0%
Graft - FTSG	0	0%
No Closure	0	0%
Shave/Saucerisation	0	0%
Liquid N2 freeze/thaw	0	0%
5 FU cream	0	0%
GP referral	0	0%
Specialist referral	0	0%
Other	0	0%

© 2026 SCARD Systems Pty Ltd

Procedures (continued)

Percentage of procedures/closures that were complex

Complex Closures	12.50% of 8
Complex Closures (inc Curettage & Cautery)	2.27% of 44

Locations

Breakdown of melanomas by location and percentage melanomas of total lesions at that location

Nose	0	0% of 9
Lip	0	0% of 2
Ear	0	0% of 6
Eyelid	0	0% of 1
Other face	1	2.56% of 39
Scalp	1	12.50% of 8
Neck	0	0% of 5
Shoulder	2	40.00% of 5
Chest	0	0% of 2
Abdomen	0	0% of 1
Genitalia	0	0% of 0
Back	5	35.71% of 14
Buttock	0	0% of 0
Arm	1	50.00% of 2
Forearm	1	6.25% of 16
Hand Dorsal	0	0% of 5
Hand Palmar	0	0% of 0
Finger Dorsal	0	0% of 1
Finger Nail	0	0% of 0
Finger Palmar	0	0% of 0
Thigh	0	0% of 2
Leg	0	0% of 12
Foot Dorsal	0	0% of 1
Foot Plantar	0	0% of 0
Toe Dorsal	0	0% of 0
Toe Nail	0	0% of 0
Toe Plantar	0	0% of 0
Palm Or Sole	0	0% of 0



© 2026 SCARD Systems Pty Ltd